Roka Bioscience Inc

Roka Bioscience — Investor Presentation (September 2016)

30 slides from Roka Bioscience's investor presentation, Sep 16, 2016

  1. Slide 1: Roka Bioscience June 2016

    CONFIDENTIAL ROKA BIOSCIENCE June 2016

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    CONFIDENTIAL Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended

  3. Slide 3: Key Highlights

    CONFIDENTIAL Key Highlights Founded in 2009 via acquisition of the industrial testing assets of Gen-Probe, a global leader in molecular diagnostics  Pure Play in Growing $2 Billion Food Safety Market*  IPO completed in July 2014  Early Adoption By Strategic Customers  Full Menu of Molecular Path

  4. Slide 4: Food Safety Testing: $2 Billion Global Market

    CONFIDENTIAL Food Safety Testing: $2 Billion Global Market Source: Capella Advisors, Company Estimates Food Safety Testing Market 4

  5. Slide 5: North American Market Growth in Molecular Testing

    CONFIDENTIAL North American Market Growth Market in Molecular Testing Market Growth Driven by Conversion to Molecular Test Volume: 75 Million SCI Food Micro 5, May 2011 & Food Micro 8 June 2013, Internal estimates ASP assumptions: Molecular $8.00/test, Antibody $5.00/test, Traditional $3.00/test 5 $

  6. Slide 6: North American Pathogen Testing Locations

    CONFIDENTIAL North American Pathogen Testing Locations Food Safety Testing Market 45 M 30 M Food Processors 3rd Party Pathogen Tests by Location 3rd Party Lab Market • Outpacing market growth • Move due to liability, technology & cost Current Testing Lab Landscape • 300-400 small labs • Fragmented

  7. Slide 7: Our food needs to be safer

    CONFIDENTIAL  Each year the CDC reports:  48 Million sick  128,000 Hospitalized  3,000 Dead  As healthier eating continues:  Increased raw fruits & veggies  Less over-cooked foods  An expectation of local and healthy  Unless something changes, there will be more outbreaks, similar to Chipot

  8. Slide 8: Technology adoption has not happened....why?

    CONFIDENTIAL Finding pathogens means additional cost of operations, e.g. diverting product, cleaning facilities, etc. Most used environmental tests (antibody-based) misses up to 50% of pathogenic bacteria* Consistent negative results satisfied regulators until now Rarely caught for poor testing,

  9. Slide 9: Processors are now caught for poor testing

    CONFIDENTIAL Processors are now caught for poor testing NEW ability to trace illness back to food 9  FSMA mandated prevention-based controls in all food processors  2015 & 2016 starts the enforcement phase  Beginning in 2013 the CDC utilizes Whole Genome Sequencing (WGS) to build database to trac

  10. Slide 10: WGS will be a change agent for the industry

    CONFIDENTIAL WGS will be a change agent for the industry  Listeria WGS launched in 2013; Salmonella, others to follow Testing to get a negative is no longer acceptable 10 Whole Genome Sequencing Impact  6 to 93 cases linked to food source in first 2 years  Traceability: Now linking outbreak to sp

  11. Slide 11: Processors want to stay out of the news

    CONFIDENTIAL Processors want to stay out of the news Representative Food borne Disease Outbreaks (2011- 2016) Product: Salad Mixes Ingredients Ice Cream Apples Chicken Peanut Butter Ground Turkey Pathogen: L. Mono STEC 026 L. Mono L. Mono Salmonella Salmonella Salmonella Case Count: 19 55 10 35 634

  12. Slide 12: Commercial Timeline

    CONFIDENTIAL Commercial Timeline  Contamination issue with Listeria encountered Q3-2014 – Significant impact on stock price and valuation  Re-development of Listeria assay – Increased robustness of assay, allowing handling by labs – Commercial launch late 2015  Commercial status – Con-Agra evalua

  13. Slide 13: Relaunch with full suite of high quality assays

    CONFIDENTIAL Relaunch with full suite of high quality assays  Listeria – NEW assay  Salmonella  E. coli O157:H7  Listeria Monocytogenes  Shiga toxin-producing E. coli (STEC) Atlas Detection AssaysAtlas Instrument Full Commercial Menu Roka Value Proposition Accurate, Rapid, Fully-Automated Test

  14. Slide 14: Proprietary Technology with Full Automation

    CONFIDENTIAL Proprietary Technology with Full Automation • Walkaway Functionality • Incorporated Process Controls • Continuous flow processing • High Throughput Capability • Removes Operator Variability Purification Target Capture Amplification TMA Detection HPA • Integrated molecular Clean Up • Rap

  15. Slide 15: Revenue Model

    CONFIDENTIAL - 50 100 150 200 250 300 350 400 Q1-2016 Average Q1-2016 High Revenue Model  Targeting labs with 75-150 tests per day  Instruments typically placed as reagent rental  Cost of instrument recovered through consumables sales  Significant revenue opportunity per instrument placed 15 *Ba

  16. Slide 16: Commercial Success to Date

    CONFIDENTIAL Commercial Success to Date 16 DoD Food Analysis & Diagnostics Laboratory *Actual customers *

  17. Slide 17: Commercial Strategy

    CONFIDENTIAL Commercial Strategy  Capitalize on new market drivers  Drive a segment focused organization  Focused promotional activities • Listeria Environmental Monitoring – all markets • Capitalize on processors fear of WGS  Key Strategic Initiatives • Partnership with significant third party

  18. Slide 18: How to Win in the Lab Market

    CONFIDENTIAL How to Win in the Lab Market  Sample Pick-Up Logistics  Leverage Existing Food Safety Business  Strong Balance Sheet  Efficient Lab Operations  Automation, flexibility  High volume, scalable instruments  Direct labor reductions 18 Enabled by Roka’s Atlas

  19. Slide 19: Significant Lab Partnership Opportunity to Drive Market

    CONFIDENTIAL Significant Lab Partnership Opportunity to Drive Market  Competitive pricing of molecular tests  Competitors will experience price erosion or lose business  Leverage existing courier infrastructure for national coverage  Offer a fast turn around time, despite shipping  Lab efficie

  20. Slide 20: Atlas Pathogen Test Pricing by Lab

    CONFIDENTIAL Atlas Pathogen Test Pricing by Lab 45.2 M 30.2 M 4% 31% 65%  Target ASP of ~ $18.00 for an Atlas pathogen test result would be an attractive and disruptive force in 3rd party testing market  Margin opportunity for both lab partner and Roka 20

  21. Slide 21: Third Party Lab Opportunity 2016-2019 Lab Revenue Potential

    CONFIDENTIAL Third Party Lab Opportunity 2016-2019 Lab Revenue Potential  Illustration of opportunity to build significant revenue for lab partner* 21 * Environmental Listeria volume only. Company estimates Assuming lab charges $18 price per test to its customers Year 1 Year 2 Year 3 Year 4 10% 44

  22. Slide 22: Laboratory Business Profitability

    CONFIDENTIAL $18 test price to end customers  Lab gross margin >35%  Exceeds current business 33% margin Laboratory Business Profitability 22 Roka gross margin >40% on sales to lab Roka pricing to lab discounted for large volume Meaningful margins for both lab and Roka

  23. Slide 23: Third Party Lab Opportunity 2016 Objectives

    CONFIDENTIAL Third Party Lab Opportunity 2016 Objectives Q1 – Atlas units into partner laboratory  Q2/Q3 – Pilot Concept  Pricing model  Courier  Atlas volume  Q4 – Agreement  Initiate broader roll-out 23

  24. Slide 24: Current Pathogen Testing in the Beef Industry

    CONFIDENTIAL Current Pathogen Testing in the Beef Industry Testing Opportunity 3.8 0.5 4.3M Pathogen Tests* E. coli 0157:H7 Salmonella/STEC Incumbent Technology BioControl GDS Regulatory Environment E. coli O157:H7 and Big Six STEC adulterants 24 *FSIS 2013 Pathogen Controls in Beef Survey, Company

  25. Slide 25: Pathway to Market Adoption

    CONFIDENTIAL Pathway to Market Adoption Roka engaged with leading beef processor over the past two years to meet external & internal adoption requirements Gain Atlas Adoption by one of the Big Four Beef Producers 25

  26. Slide 26: Current Status

    CONFIDENTIAL Current Status Customer already uses Atlas for all Poultry testing and recognizes efficiencies Industry conservative on making testing change due to recent litigations on E.Coli O157:H7  Risk of change offset by significant cost savings benefit Significant cost savings estimated by

  27. Slide 27: Beef Market Opportunity

    CONFIDENTIAL Beef Market Opportunity 27 3.8 0.5 4.3M Pathogen Tests E. coli 0157:H7 Salmonella/STEC 4 large processors *Revenue based on $8.00 per test Revenue ($ mill.)* 25% 9 50% 17 75% 26 100% 34 Sh ar e FSIS 2013 Pathogen Controls in Beef Survey, Company Estimates

  28. Slide 28: Funding Summary

    CONFIDENTIAL Funding Summary  Well positioned to benefit from a changing food safety market  Lab partnership and beef present exciting opportunities  $25M Financing sought to fund significant revenue growth  Insider participation by leading investors 28

  29. Slide 29: Cap Table March 31, 2016

    CONFIDENTIAL Cap Table March 31, 2016 52% 29 Shares outstanding (millions) 17.9 100% OrbiMed 3.2 18% NEA 3.2 18% TPG 2.9 16% Other insiders 1.0 6% Craig Drill 1.6 9% Hologic 0.9 5% Aisling 0.5 3% Others 4.5 25%

  30. Slide 30: Balance Sheet Summary

    CONFIDENTIAL Balance Sheet Summary  $25.5 working capital  $3.0 debt principal due by end of 2016 ($ Million) 31-Mar-16 Cash and equivalents 23.3 Property and equipment 9.4 Intangible assets 21.5 Other assets 10.0 Debt 9.0 Deferred payments 4.1 Other liabilities 13.9 Equity 37.2 30

Roka BioScience — Investor Presentation (September 2016) on 6ix